| Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population EU Griese, UM Zanger, U Brudermanns, A Gaedigk, G Mikus, K Mörike, ... Pharmacogenetics and Genomics 8 (1), 15-26, 1998 | 418 | 1998 |
| Gabapentin enhances the analgesic effect of morphine in healthy volunteers K Eckhardt, S Ammon, U Hofmann, A Riebe, N Gugeler, G Mikus Anesthesia & Analgesia 91 (1), 185-191, 2000 | 357 | 2000 |
| Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study C Pauli-Magnus, G Mikus, DM Alscher, T Kirschner, W Nagel, N Gugeler, ... Journal of the American Society of Nephrology 11 (3), 514-519, 2000 | 305 | 2000 |
| Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation K Eckhardt, S Li, S Ammon, G Schänzle, G Mikus, M Eichelbaum Pain 76 (1-2), 27-33, 1998 | 304 | 1998 |
| European Pain Federation position paper on appropriate opioid use in chronic pain management T O'Brien, LL Christrup, AM Drewes, MT Fallon, HG Kress, HJ McQuay, ... European Journal of Pain 21 (1), 3-19, 2017 | 246 | 2017 |
| Pharmacokinetics of (+)‐,(‐)‐and (+/‐)‐verapamil after intravenous administration. M Eichelbaum, G Mikus, B Vogelgesang British journal of clinical pharmacology 17 (4), 453-458, 1984 | 242 | 1984 |
| CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole J Weiss, MM Ten Hoevel, J Burhenne, I Walter‐Sack, MM Hoffmann, ... The Journal of Clinical Pharmacology 49 (2), 196-204, 2009 | 238 | 2009 |
| First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B A Blank, C Markert, N Hohmann, A Carls, G Mikus, T Lehr, A Alexandrov, ... Journal of hepatology 65 (3), 483-489, 2016 | 231 | 2016 |
| Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype I Scholz, H Oberwittler, KD Riedel, J Burhenne, J Weiss, WE Haefeli, ... British journal of clinical pharmacology 68 (6), 906-915, 2009 | 214 | 2009 |
| Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers R Ding, Y Tayrouz, KD Riedel, J Burhenne, J Weiss, G Mikus, WE Haefeli Clinical Pharmacology & Therapeutics 76 (1), 73-84, 2004 | 196 | 2004 |
| Opposite effects of short‐term and long‐term St John's wort intake on voriconazole pharmacokinetics J Rengelshausen, M Banfield, KD Riedel, J Burhenne, J Weiss, ... Clinical Pharmacology & Therapeutics 78 (1), 25-33, 2005 | 192 | 2005 |
| Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir G Mikus, V Schöwel, M Drzewinska, J Rengelshausen, R Ding, KD Riedel, ... Clinical Pharmacology & Therapeutics 80 (2), 126-135, 2006 | 180 | 2006 |
| Pharmacokinetics of oral and intravenous rifampicin during chronic administration U Loos, E Musch, JC Jensen, G Mikus, HK Schwabe, M Eichelbaum Klinische Wochenschrift 63, 1205-1211, 1985 | 176 | 1985 |
| Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction J Rengelshausen, C Göggelmann, J Burhenne, KD Riedel, J Ludwig, ... British journal of clinical pharmacology 56 (1), 32-38, 2003 | 162 | 2003 |
| Granulocyte colony–stimulating factor in patients with acute ischemic stroke: results of the AX200 for ischemic stroke trial EB Ringelstein, V Thijs, B Norrving, A Chamorro, F Aichner, M Grond, ... Stroke 44 (10), 2681-2687, 2013 | 151 | 2013 |
| The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans DA Capon, F Bochner, N Kerry, G Mikus, C Danz, AA Somogyi Clinical Pharmacology & Therapeutics 60 (3), 295-307, 1996 | 148 | 1996 |
| Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine PE Meissner, G Mandi, B Coulibaly, S Witte, T Tapsoba, U Mansmann, ... Malaria journal 5, 1-5, 2006 | 147 | 2006 |
| Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide R Klimas, G Mikus British journal of anaesthesia 113 (6), 935-944, 2014 | 146 | 2014 |
| Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals N Hohmann, G Mikus, D Czock Deutsches Ärzteblatt International 111 (9), 139, 2014 | 146 | 2014 |
| Pharmacokinetic modelling of morphine, morphine‐3‐glucuronide and morphine‐6‐glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short‐term infusion … I Meineke, S Freudenthaler, U Hofmann, E Schaeffeler, G Mikus, ... British journal of clinical pharmacology 54 (6), 592-603, 2002 | 143 | 2002 |
Andrew SomogyiUniversity of Adelaide, Discipline of Pharmacology在 adelaide.edu.au 的电子邮件经过验证
